UF startup Axogen, Inc., a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral nerve function, announced that the U.S. Food and Drug Administration has approved the Biologics License Application for AVANCE® (acellular nerve allograft-arwx).
Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged 1 month or older with sensory, mixed, and motor peripheral nerve discontinuities.
Read more about Axogen Announces FDA Approval of Biologics License Application for AVANCE®.
